Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis-Reference-Cited by-全球学者库

Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis

Published:2010-11-16 Issue:6 Volume:12 Page:
ISSN:1478-6362
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Liu Yanying,Mu Rong,Wang Shiyao,Long Li,Liu Xia,Li Ru,Sun Jian,Guo Jianping,Zhang Xiaoping,Guo Jing,Yu Ping,Li Chunlei,Liu Xiangyuan,Huang Zhenyu,Wang Dapeng,Li Hu,Gu Zhifeng,Liu Bing,Li Zhanguo

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/ar3187.pdf

Reference45 articles.

1. Van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM: Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann Rheum Dis. 2005, 64: 537-543. 10.1136/ard.2004.024927.

2. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT: Rituximab therapy reduces activated B cells both in the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009, 11: R131-10.1186/ar2798.

3. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register: Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006, 54: 1786-1794. 10.1002/art.21830.

4. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low- results from RABBIT, the German biologics register. Arthritis Res Ther. 2006, 8: R66-10.1186/ar1933.

5. Nakae S, Nambu A, Sudo K, Iwakura Y: Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003, 171: 6173-6177.

Cited by 185 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gingival mesenchymal stem cells derived from patients with rheumatoid arthritis treats experimental arthritis;2023-11-07

2. Cell‐based therapies for the treatment of rheumatoid arthritis;Immunity, Inflammation and Disease;2023-11

3. Rheumatoid arthritis: the old issue, the new therapeutic approach;Stem Cell Research & Therapy;2023-09-23

4. IL-1β stimulated human umbilical cord mesenchymal stem cells ameliorate rheumatoid arthritis via inducing apoptosis of fibroblast-like synoviocytes;Scientific Reports;2023-09-15

5. Umbilical cord mesenchymal stem cells relieve osteoarthritis in rats through immunoregulation and inhibition of chondrocyte apoptosis;Scientific Reports;2023-09-11